16/05/2026
Metabolic-associated fatty liver disease (MAFLD) is the most common chronic liver disease, affecting approximately one quarter of the adult population worldwide. It is characterized by the accumulation of excess fat in hepatocytes.
MAFLD is closely associated with other metabolic disorders, including insulin resistance, diabetes mellitus, and obesity. Timely prevention and treatment help prevent the development of hepatitis, cirrhosis, and liver cancer. Undoubtedly, weight reduction, lifestyle modification, healthy nutrition, abstinence from alcohol, and increased physical activity have a positive impact on the treatment of MAFLD.
Fetal stem cell therapy at EmCell promotes the regeneration of healthy hepatocytes, improves liver function, reduces intrahepatic lipid content, inflammation, and fibrosis, and exerts metabolic effects by contributing to weight loss, lowering blood pressure, reducing insulin resistance, and normalizing lipid profiles and carbohydrate metabolism.